Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes.

ABSTRACT:

What is already known about this subject

• Population pharmacokinetics and pharmacodynamics of rivaroxaban have been characterized in healthy subjects and in patients with total venous thromboembolism, deep vein thrombosis or atrial fibrillation.

What this study adds

• This article is the first description of the population pharmacokinetics (PK) and pharmacodynamics (PD) of rivaroxaban in patients with acute coronary syndrome (ACS). It is the largest population pharmacokinetic and pharmacodynamic study on rivaroxaban conducted to date (n= 2290). The PK and PK-PD relationship of rivaroxaban in patients with ACS were similar to those in other patient populations. In addition, model-based simulations showed that the influence of renal function and age on the exposure to rivarox

SUBMITTER: Xu XS 

PROVIDER: S-EPMC3394132 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature